December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
11 citations
,
May 2019 in “Journal of Cosmetic Dermatology” Mesotherapy helps treat male hair loss effectively.
November 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
23 citations
,
March 1994 in “Fertility and sterility” Most patients improved with oral contraceptives, but some needed additional treatment.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
Anti-androgens can help treat tough skin conditions like severe acne and excessive hair growth.
38 citations
,
February 2019 in “Clinical Interventions in Aging” Dutasteride more effectively treats hair loss than finasteride, but may increase risk of altered libido.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
November 2020 in “TURKDERM” Hormonal treatments effectively manage acne in some women, especially with specific hormonal issues.
1 citations
,
April 2020 in “Journal of The American Academy of Dermatology” 5ARI treatment improves hair growth in older men with minimal side effects.
March 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” Using dutasteride during hair transplants improves results and reduces hair loss.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
2 citations
,
July 2017 in “Oman medical journal” A man with a rare adrenal cancer showed unusual symptoms and died four months after diagnosis.
9 citations
,
September 2009 in “The Prostate” Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
July 2025 in “Ultrasound in Medicine & Biology”
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
6 citations
,
June 2021 in “EClinicalMedicine” ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
January 2008 in “프로그램북(구 초록집)”
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
78 citations
,
March 1989 in “The Journal of Clinical Endocrinology & Metabolism” High-dose androgen therapy can help manage certain types of androgen resistance.
August 2025 in “Journal of the American Academy of Dermatology” 1 citations
,
July 2022 in “JEADV Clinical Practice” New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
1 citations
,
December 1971 in “PubMed”
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
1 citations
,
June 2016 in “Annals of the rheumatic diseases” Retinoids may help treat lupus nephritis and reduce steroid use.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
January 2013 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” Chemotherapy causes temporary hair loss and discomfort, while tamoxifen has minimal hair effects.
31 citations
,
September 2020 in “Clinical endocrinology” Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.